ADXN.SW Stock Down 1.7% Pre-Market: Earnings May 18

Addex Therapeutics Ltd (ADXN.SW) is trading at CHF0.045 on the SIX exchange, down 1.7% in pre-market activity on May 13, 2026. The Geneva-based biotech company focuses on small-molecule treatments for central nervous system disorders. With earnings scheduled for May 18, investors are watching ADXN.SW stock closely. The company’s lead programs include Dipraglurant for Parkinson’s disease and ADX71149 for epilepsy. Meyka AI rates ADXN.SW stock with a B- grade, suggesting a hold position amid ongoing clinical development.

ADXN.SW Stock Price and Market Performance

ADXN.SW stock opened at CHF0.045 with a day range of CHF0.045 to CHF0.048. The stock has declined 1.75% today, reflecting broader market weakness in biotech. Over the past year, ADXN.SW stock has fallen 24.5%, while the 52-week high stands at CHF0.085 and the low at CHF0.0336.

Market cap sits at CHF6.65 million with 147.8 million shares outstanding. Volume reached 232,949 shares, slightly above the 223,357 average. The 50-day moving average is CHF0.04478, while the 200-day average is CHF0.054151, indicating downward pressure on ADXN.SW stock.

Financial Metrics and Valuation of ADXN.SW Stock

ADXN.SW stock shows negative earnings with an EPS of -CHF0.06 and a PE ratio of -0.75. The price-to-sales ratio is elevated at 43.49x, reflecting the company’s minimal revenue generation. Book value per share stands at CHF0.0334, giving a price-to-book ratio of 1.35x.

Key metrics reveal operational challenges. Operating cash flow per share is -CHF0.0152, while free cash flow per share is also negative at -CHF0.0152. The current ratio of 1.40x suggests adequate short-term liquidity. Debt-to-equity remains low at 0.73%, indicating conservative leverage. Track ADXN.SW on Meyka for real-time updates on these metrics.

Meyka AI Rating and Technical Analysis

Meyka AI rates ADXN.SW stock with a grade of B-, suggesting a hold recommendation. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The rating reflects mixed signals across profitability and valuation metrics.

Technically, ADXN.SW stock shows weakness. The RSI stands at 47.52, near neutral territory. The CCI at -108.41 indicates oversold conditions. Williams %R at -78.13 signals potential downside pressure. MACD is flat at 0.00 with no clear directional bias. These technical indicators suggest ADXN.SW stock lacks strong momentum heading into earnings.

Earnings Announcement and Forward Outlook

Addex Therapeutics will announce earnings on May 18, 2026, at 15:30 UTC. This earnings call is critical for ADXN.SW stock investors tracking clinical progress and cash burn rates. The company’s development-stage status means revenue remains minimal, with focus on R&D spending and partnership updates.

Forecasts project ADXN.SW stock at CHF0.03 monthly and CHF0.05 quarterly. The yearly forecast is CHF0.0316, implying downside from current levels. Three-year projections show CHF0.0118, reflecting long-term uncertainty. These forecasts are model-based projections and not guarantees. Investors should monitor clinical trial updates and partnership announcements with Janssen Pharmaceuticals and Indivior PLC.

Final Thoughts

ADXN.SW stock faces headwinds as a development-stage biotech with negative earnings and minimal revenue. Trading at CHF0.045 on the SIX exchange, the stock has declined significantly over the past year. Meyka AI’s B- rating reflects balanced risk-reward dynamics. The May 18 earnings announcement will be pivotal for ADXN.SW stock sentiment, likely focusing on clinical trial progress and cash runway. Investors should weigh the company’s promising CNS drug pipeline against its current financial challenges. These grades are not guaranteed and we are not financial advisors.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.